ORCHESTRA BIOMED HOLDINGS INC

Orchestra BioMed Holdings, Inc. is a clinical-stage biomedical company whose product pipeline is built on preclinical animal testing. Its lead candidates, AVIM Therapy for hypertension and the Virtue SAB for coronary in-stent restenosis, required extensive animal studies to demonstrate safety and efficacy prior to human clinical trials. This reliance on animal models is standard for the medical device and biopharmaceutical sector, placing the company within the broad category of commercial animal exploitation for research and development.

While Orchestra BioMed’s specific animal testing protocols are not detailed in public filings, the company operates within an industry and regulatory framework where animal testing is a prerequisite. A 2025 audit report compiled by Cruelty Free Investors documented hundreds of animal welfare violations across U.S. laboratories, indicating systemic risks of animal suffering inherent in industrial-scale biomedical research. As a developer of implantable devices and biologic solutions, Orchestra BioMed’s research activities contribute to this commercial ecosystem.